On August 22nd, the “AI ON INTEL” Technology Partnership Workshop was held in Singapore. Huiying Medical, an Intel® AI Builders member, was invited to share its experience as the only Chinese medical imaging AI company.
At the “AI ON INTEL” conference, top AI practitioners and Intel experts shared and discussed the new possibilities and future of AI applications. The keynote speech “Medical Imaging AI on Practice,” presented by Chai Xiangfei, founder and CEO of Huiying Medical, analyzed the current state and looked at the future of the application of AI in the medical imaging field.
At its current stage, AI is primarily utilized to ease large-scale, repetitive, and time-consuming work, a development that has brought great benefits to medical care such as helping clinicians quickly and efficiently analyze imagery and diagnose critical cases with high accuracy. In the future, artificial intelligence will provide even greater value in clinical relevance, clinical verification, workflow integration, and increased return on investment.
Partnership Delivers Results
Lung cancer is the most commonly diagnosed cancer (11.6% of total cases) and it is the leading cause of cancer deaths (accounting for 18.4% of cancer deaths)1. Early screening for lung cancer not only saves lives, but also reduces economic pressure on patients.
At the conference, Huiying Medical released a new generation of its AI-assisted diagnosis application called “Dr. Turing CT lung cancer edge-cloud collaborative solution”, powered by 2nd Generation Intel Xeon® Scalable Processors and optimized with the Intel® Distribution of OpenVINO™ Toolkit. The solution supports deployment both at the edge and in the cloud. Based on the ‘cloud + edge’ architecture, AI technologies can be made available at local clinics and reach a broad community of end-users; therefore solve the problems of shortage in medical resources and improve the diagnostic accuracy. The solution boosts the cloud computing inference performance substantially and achieves higher accuracy through algorithm optimization.
Since its establishment in 2015, Huiying Medical has been committed to solving medical problems with science and technology and to using technology to serve the real needs of patients and doctors. In the future, Huiying Medical will continue to empower medical imaging innovation with artificial intelligence, big data, cloud computing, 5G and other cutting-edge technologies to address pain points in clinical work flow and develop a leading artificial intelligence engine and big data platform to enable full life-cycle AI solutions for healthcare.
In another use case, collaborating with Intel engineers, Huiying Medical has improved the inference performance by 8.24X for early breast cancer detection by leveraging the Intel Distribution of OpenVINO toolkit on Intel Xeon Scalable processors2. Learn more in the Solution Brief, Huiying Medical Technology Optimizes Breast Cancer Early Screening and Diagnosis with Intel® AI Technologies
The close partnership with the Intel AI Builders program enables Huiying Medical to accelerate their path to bringing innovative AI driven medical imaging solutions to doctors and patients; helping them benefit from efficient, accurate and readily available healthcare solutions and services that can improve lives.
Link to lung nodule detection solution: https://builders.intel.com/ai/solutionscatalog/lung-nodule-detection-551
Link to breast cancer detection solution: